ArticleScientific reports2026
Synergistic anticancer effects of lipoplex-encapsulated Q7 peptide and doxorubicin against endometrial cancer cells.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer remains a major gynecological malignancy with a rising incidence and limited treatment options for advanced cases. Our previous study demonstrated that the Q7 anticancer peptide exerts its effects by suppressing DHCR24, regulating the AKT pathway, and inducing apoptosis in HEC-1-A endometrial cancer cells. In this study, Q7 significantly inhibits proliferation, migration, and invasion, potentially by modulating lipid metabolism and cytoskeletal remodeling pathways. Notably, Q7 transiently upregulates epithelial-mesenchymal transition (EMT)-related genes at early time points but ultimately suppresses tumor motility. To enhance its therapeutic efficacy, we encapsulated Q7 in lipoplex nanoparticles (LPPC-Q7), which exhibited superior tumor-suppressive effects both in vitro and in vivo. Furthermore, combining LPPC-Q7 with doxorubicin (LPPC-Q7-DOX) produced a synergistic effect, leading to enhanced tumor growth suppression, apoptosis induction, and inhibition of exosome production and metastasis. These findings highlight LPPC-Q7-DOX as a promising therapeutic strategy for endometrial cancer, effectively targeting lipid metabolism and cytoskeletal dynamics to combat tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.